Quest Diagnostics Boosts FY26 Outlook; Shares Up 5.7% - Update
Quest Diagnostics (DGX) reported Q2 results and raised its FY2026 guidance. It now expects GAAP earnings of $9.97 to $10.17 per share and adjusted earnings of $11.05 to $11.25, on revenue of $11.95B to $12.05B, versus prior ranges of $9.58 to $9.78, $10.63 to $10.83, and $11.78B to $11.90B. Shares were up 5.71% premarket.
How this was made
The 30-second read
Why it matters
The guidance increase narrows the risk range for FY26 earnings and can re-anchor valuation expectations for the next earnings cycle.
Market read
A full-year guidance raise with specific EPS and revenue ranges is a direct catalyst for DGX positioning.
What to watch
The article provides ranges but not the underlying drivers (volume, pricing, mix, costs), so traders should verify whether margins and cash flow are improving alongside EPS.
Background
Quest Diagnostics reported Q2 results and simultaneously updated its full-year 2026 outlook.
Ticker impact
Quest Diagnostics raised FY26 earnings and adjusted earnings guidance, projecting $9.97-$10.17 EPS and $11.05-$11.25 adjusted EPS on $11.95-$12.05B revenue.
Likely continued upward bias in the near term, with follow-through dependent on whether the raised ranges clear Street expectations.
The article discloses a concrete, full-year guidance increase with specific EPS and revenue ranges, and notes a same-day pre-market share jump.
Market effects
Positive read-through for diagnostic services demand visibility if peers interpret the guidance as stable utilization and pricing.
Primarily US large-cap healthcare sentiment via a major lab services name.
Limited direct global impact; mostly affects US healthcare diagnostics expectations.
Counterpoint
The raised guidance could still be below consensus, so the stock may fade if the market had already priced in an improvement.
Key entities
- companyQuest Diagnostics, Inc.
Raised FY26 earnings, adjusted earnings, and revenue guidance after reporting Q2 results.
